Adeno-associated virus (AAV) vectors are frequently utilized as viral vectors for gene therapy.
NYS Entity Status
NYS Filing Date
MARCH 04, 2014
NYS DOS ID#
NYS Entity Type
FOREIGN BUSINESS CORPORATION
2014 - GENE BURTON & ASSOCIATES, INC.
AROUND THE WEB
- How Exactly Does Gene Transfer via AAV Work?
Friday Jul 14, 2017
- MSH3 Gene Reveals Critical Link With Huntington’s Disease
Wednesday Aug 9, 2017
A recent study published in Lancet Neurology reveals important associations between MSH3 gene mutations and Huntington’s disease progression and disease burden.
- LeVar Burton Sued in ‘Reading Rainbow’ Copyright Dispute
By Tim Kenneally, provided by
- Monday Aug 7, 2017
In the suit, filed in federal court in New York on Friday, Buffalo-based PBS affiliate WNED maintains that it owns the rights to intellectual property associated with “Reading Rainbow,” and agreed to license the property to Burton for an online revival of the series in 2011.According to WNED, Burton’s company RRKidz has challenged the termination, leaving the two entities embroiled in contentious litigation arising out of that termination for the better part of two years.According to the suit, a court ordered RRKidz not to represent that Burton owns Reading Rainbow in Oct. 2016, but the media “latched onto Mr. Burton’s use of the phrase ‘Reading Rainbow for adults,’ and it became the de facto slogan for [his] podcast.”The suit is asking for an order preventing RRKids from “reproducing, distributing, publicly performing, or publicly displaying content substantially similar to the RR Series, other than the continued distribution of content created prior to March 18, 2016 through Reading Rainbow Skybrary, as that product existed at the time of the termination of the License Agreement.”
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]
- Ryder Trucks Launches Campaign With 'Inc.'
Tuesday Sep 19, 2017
"The campaign underscores how truck owners are essentially dumping cash all over America's highways from all the hidden costs required in maintaining a private fleet," Ryder's Karen Jones tells"Marketing Daily."
- Homology Med Bags $83.5M More, Fueling Push For Gene Editing Twist
By Ben Fidler - Tuesday Aug 1, 2017
One day after the release of a Nature Medicine paper warning of the potential hazards of testing CRISPR-Cas9 gene editing in humans, Homology Medicines, a startup advancing a different genetic surgery technique, has just grabbed a big round of funding to make its own clinical push. Homology, of Bedford, MA, wrapped up an $83.5 million […]